Oxaliplatin as a radiosensitizing agent in rectal cancer

University of Texas Southwestern Medical Center, Dallas, Texas 75216, USA.
Anti-cancer drugs (Impact Factor: 1.78). 04/2011; 22(4):317-23. DOI: 10.1097/CAD.0b013e328343e076
Source: PubMed


The efficacy of oxaliplatin monotherapy against several solid tumors and its relative lack of nephrotoxicity and myelosupression, coupled with results of the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer trial, led to a great deal of interest for the implementation of this chemotherapeutic agent in the preoperative setting for the management of adenocarcinoma of the rectum. Despite limited in-vitro and in-vivo data with regard to the radiosensitizing properties of oxaliplatin in rectal cancer, it rapidly entered phase I-III clinical trials. This study reviews the results of these trials and the current status of oxaliplatin as a radiosensitizing agent in the neoadjuvant management of rectal cancer.

1 Read
  • [Show abstract] [Hide abstract]
    ABSTRACT: The current management of rectal cancer in the preoperative setting provides a unique opportunity to explore individualized patient care. The management of adenocarcinoma of the rectum must involve a multidisciplinary approach. The distinctive feature of rectal tumors to either achieve complete resolution or no response in patients submitting to the same treatment modalities demonstrates that the biology of rectal tumors requires further insights. An understanding of the biology of rectal tumors might permit for selection of patients with an aggressive phenotype allowing for alterations in the operative and neoadjuvant planning. The critical concepts in the oncogenesis of rectal cancer are areas of dynamic progression and require constant assessment.
    Critical reviews in oncogenesis 11/2012; 17(4):323-9. DOI:10.1615/CritRevOncog.v17.i4.20
  • [Show abstract] [Hide abstract]
    ABSTRACT: Over the past couple of decades, with discovery of novel targeted therapies, and expansion of our understanding of the molecular biology of rectal cancer, there has been an emergence of a wide variety of therapeutic options designed to facilitate a personalized approach for the treatment of this malignancy. A plethora of new prognostic and predictive single genes and proteins are being discovered that may reflect susceptibility and/or resistance to therapy. Pathologic complete response rates occur in 10-16% of patients and have been shown to correlate with both disease-free and overall survival. However, the response to neoadjuvant therapy remains variable and unpredictable. In this review, some of these novel markers are discussed for their potential use as pharmacogenetic predictors for specific therapy, drug toxicity, and disease outcome.
    Critical reviews in oncogenesis 11/2012; 17(4):361-72. DOI:10.1615/CritRevOncog.v17.i4.50
  • [Show abstract] [Hide abstract]
    ABSTRACT: The management of locally advanced rectal cancer requires a multidisciplinary effort. Surgical resection remains the therapeutic cornerstone, but neoadjuvant chemoradiation clearly improves both surgical and long-term outcomes. Pathological complete response is a desirable outcome and has been associated with good long-term outcomes. This article provides an overview of the evolution and current role of radiosensitizing chemotherapy when given as part of neoadjuvant chemoradiation for locally advanced rectal cancer. 5-fluorouracil, given either as an infusion or orally as capecitabine, appears to have the most favorable balance of efficacy and tolerability at the present time. Oral administration without need for central IV access makes capecitabine an attractive option. Oxaliplatin and irinotecan have demonstrated increased toxicity without substantial associated improvement in outcomes. Both bevacizumab and cetuximab appear feasible when given with radiosensitizing chemotherapy, but no strong signal of improved efficacy has been demonstrated so far. There is currently a great need for new radiosensitizing agents and predictive biomarkers to help optimize the use of existing therapeutics. Increased topoisomerase I expression and increased EGFR gene copy number as possible predictors of response to irinotecan- and cetuximab-based chemoradiation, respectively, deserve further studies.
    Critical reviews in oncogenesis 11/2012; 17(4):345-59. DOI:10.1615/CritRevOncog.v17.i4.40
Show more